Histrelin Acetate (Vantas®)

Common name: Histrelin Acetate
Brand name: Vantas®
 

What is Histerlin Acetate?

Histrelin Acetate is a palliative treatment for men diagnosed with hormone-dependent advanced (metastatic) prostate cancer.
 

How is Histrelin Acetate administered?

Histerlin Acetate is a placed under the skin (subcutaneous) as a subdermal implant.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received histrelin. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Abdominal pain
  • Dark urine
  • Difficulties breathing
  • Local infection
  • Loss of appetite
  • Nausea
  • Reduced testicle size
  • Vomiting
  • Weight gain
 

Is histrelin acetate covered in my province or territory?

Provincial/Territorial Drug Program Coverage: Unknown 
 

 
Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More

Rocco Rossi to wrap up successful 5-year tenure as Prostate Cancer Canada CEO

September 7, 2017 - TORONTO, ON - With mixed emotions, longstanding Prostate Cancer Canada (PCC) President and CEO, Rocco Rossi, formally announced today that his time leading the organization will officially come to a close as of December 31, 2017.
More


Click here for news archive